Anti-scopolamine monoclonal antibody as well as application and product thereof
By preparing high-purity, high-sensitivity anti-scopolamine monoclonal antibodies, the problems of high cost and time consumption in existing detection methods have been solved, enabling rapid, simple, and accurate detection of scopolamine, which is suitable for immunological detection.
Patent Information
- Application Number
- CN202411181073.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-27
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2044-08-27
AI Technical Summary
Existing methods for detecting scopolamine are expensive and time-consuming, requiring specialized technicians to operate, and cannot meet the requirements of modern testing for simplicity, speed, and accuracy.
Using anti-scopolamine monoclonal antibodies, highly specific hybridoma cells were obtained through high-throughput screening. High-purity and high-sensitivity anti-scopolamine monoclonal antibodies were prepared for immunological detection and conjugated with markers to prepare immunoassay kits.
It enables rapid, sensitive, and accurate detection of scopolamine, simplifies the operation process, reduces detection costs, and is suitable for immunological detection methods such as immunoblotting and immunofluorescence.
Smart Images

Figure BDA0005012181140000051 
Figure BDA0005012181140000061 
Figure BDA0005012181140000091
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, and in particular to an anti-scopolamine monoclonal antibody and an application and product thereof. Background Art
[0002] Scopolamine (hyoscine) is a tropane alkaloid, mainly found in Solanaceae plants, such as Solanum belladonna and Datura, and is the main alkaloid in Datura stramonium, Hyoscyamus scopolamine and Hyoscyamus henbun. In clinical practice, scopolamine is mainly used for analgesia, anesthesia, anti-motion sickness, Parkinson's disease, improving microcirculation, drug addiction, pesticide poisoning, etc., and the market demand is huge.
[0003] In recent years, scopolamine has been increasingly used in clinical medicine and has achieved remarkable therapeutic effects. For example, it has important uses in the treatment of respiratory diseases, septic shock, cardiovascular diseases, digestive diseases, nervous system diseases and other diseases. Its adverse reactions generally include dry mouth, thickened secretions, flushed face, restlessness, agitation, hallucinations, delirium, urinary retention, blurred vision, abdominal distension, fever, etc.; occasionally, arrhythmias, convulsions, coma, etc. Scopolamine has a sedative effect in small doses and a hypnotic effect in large doses. Therefore, it is necessary to establish a rapid, sensitive and accurate method for detecting scopolamine, which will help determine the abuse of scopolamine.
[0004] At present, the detection of scopolamine mainly relies on gas chromatography-mass spectrometry (GC-MS), liquid chromatography quadrupole time-of-flight mass spectrometry (Q-TOF LC / MS), nuclear magnetic resonance hydrogen spectrum (H NMR), nuclear magnetic resonance carbon spectrum (13C NMR), nuclear magnetic resonance fluorine spectrum (19F NMR), infrared spectroscopy (IR) and other methods. However, all of them have the disadvantages of expensive instruments, time-consuming detection, and the need for professional technicians to operate. Therefore, they cannot meet the requirements of modern detection for simplicity, speed and accuracy.
[0005] In view of this, the present invention is proposed. Summary of the invention
[0006] The first object of the present invention is to provide an anti-scopolamine monoclonal antibody to solve the problem of scopolamine detection.
[0007] A second object of the present invention is to provide a biomaterial.
[0008] The third object of the present invention is to provide a method for preparing the above-mentioned anti-scopolamine monoclonal antibody.
[0009] The fourth object of the present invention is to provide the use of the above-mentioned anti-scopolamine monoclonal antibody in the preparation of a scopolamine detection product.
[0010] A fifth object of the present invention is to provide a marker for scopolamine.
[0011] A sixth object of the present invention is to provide a kit for detecting scopolamine.
[0012] In order to achieve the above objectives, the following technical solutions are adopted:
[0013] In the first aspect, the present invention provides an anti-scopolamine monoclonal antibody, the variable region of the anti-scopolamine monoclonal antibody comprising: a complementary determining region CDR1-VH having an amino acid sequence as shown in SEQ ID NO.1, a complementary determining region CDR2-VH having an amino acid sequence as shown in SEQ ID NO.2, a complementary determining region CDR3-VH having an amino acid sequence as shown in SEQ ID NO.3, a complementary determining region CDR1-VL having an amino acid sequence as shown in SEQ ID NO.4, a complementary determining region CDR2-VL having an amino acid sequence as shown in SEQ ID NO.14, and a complementary determining region CDR3-VL having an amino acid sequence as shown in SEQ ID NO.5.
[0014] As a further technical solution, the variable region includes a heavy chain variable region VH having an amino acid sequence as shown in SEQ ID NO.6;
[0015] The variable region includes a light chain variable region VL having an amino acid sequence as shown in SEQ ID NO.7.
[0016] As a further technical solution, the anti-scopolamine monoclonal antibody is an IgG antibody.
[0017] In a second aspect, the present invention provides a biomaterial, wherein the biomaterial is selected from any one of ac:
[0018] a. a nucleotide comprising a nucleotide sequence encoding the anti-scopolamine monoclonal antibody;
[0019] b. a vector carrying the nucleotides in a;
[0020] c. A cell, wherein the cell carries the nucleotide described in a, or contains the vector described in b, or expresses the anti-scopolamine monoclonal antibody.
[0021] In a third aspect, the present invention provides a method for preparing the above-mentioned anti-scopolamine monoclonal antibody, which is obtained by fermenting the above-mentioned cells.
[0022] In a fourth aspect, the present invention provides use of the above-mentioned anti-scopolamine monoclonal antibody in the preparation of a scopolamine detection product.
[0023] In a fifth aspect, the present invention provides a scopolamine marker, comprising the anti-scopolamine monoclonal antibody and a marker;
[0024] The anti-scopolamine monoclonal antibody is coupled to a label.
[0025] As a further technical solution, the marker includes an enzyme, a fluorescent molecule marker, a fluorescent microsphere, a colored microsphere, colloidal gold, biotin or streptavidin.
[0026] In a sixth aspect, the present invention provides a kit for detecting scopolamine, the kit comprising the anti-scopolamine monoclonal antibody or the scopolamine marker.
[0027] As a further technical solution, the kit includes an immunochromatographic detection kit, an ELISA detection kit, an immunomagnetic particle detection kit, an immunofluorescence detection kit or an immunoblotting detection kit.
[0028] Compared with the prior art, the present invention has the following beneficial effects:
[0029] The present invention uses scopolamine to immunize Balb / c mice, takes mouse spleen cells and fuses them with myeloma cells, obtains highly specific hybridoma cells through specific high-throughput screening, obtains a large amount of mouse ascites through culture and re-immunization, and then obtains high-purity, high-sensitivity and high-specificity anti-scopolamine monoclonal antibody anti-hyoscine-mab1 through multi-step separation and purification, providing the required raw materials for developing immune test strips for detecting scopolamine. The anti-scopolamine monoclonal antibody anti-hyoscine-mab1 of the present invention can be used for immunological detection such as immunoblotting and immunofluorescence, and the obtained antibody has been verified to have good specific binding ability. DETAILED DESCRIPTION
[0030] The embodiments of the present invention will be described in detail below in conjunction with the embodiments and examples, but it will be appreciated by those skilled in the art that the following embodiments and examples are only used to illustrate the present invention and should not be considered as limiting the scope of the present invention. Based on the embodiments in the present invention, all other embodiments obtained by those of ordinary skill in the art without making creative work are within the scope of protection of the present invention. If specific conditions are not specified, proceed according to normal conditions or conditions recommended by the manufacturer. If the manufacturer is not specified for the reagents or instruments used, they are all conventional products that can be purchased commercially.
[0031] Generally, the nomenclature and its technology used in conjunction with cell and tissue culture, molecular biology, immunology, microbiology, genetics, and protein and nucleic acid chemistry and hybridization described herein are those well-known and commonly used in the art. Unless otherwise indicated, the methods and techniques of the present invention are generally carried out according to conventional methods as well-known in the art, and as described in various general and more specific references, which are cited and discussed throughout this specification. Enzymatic reactions and purification techniques are carried out according to the manufacturer's specifications, as generally achieved in the art, or as described herein. The nomenclature and its laboratory procedures and technology used in conjunction with analytical chemistry, synthetic organic chemistry, and medical and pharmaceutical chemistry described herein are those well-known and commonly used in the art.
[0032] The "variable region" or "variable domain" of an antibody refers to the domain at the amino terminus of the heavy chain or light chain of the antibody that recognizes and binds to the antigen. The composition and arrangement of the amino acids in this segment determine the specificity of the antibody in recognizing the antigen. The heavy chain variable region can be referred to as "VH". The light chain variable region can be referred to as "VL". These domains are usually the most variable parts of the antibody and contain antigen binding sites. The variable regions of the heavy and light chains are each composed of three complementarity-determining regions (CDRs) (also called hypervariable regions) connected by four framework regions (FRs). The CDRs in each chain are held together closely by FRs to form the variable region. Typically, the variable regions VL / VH of the heavy and light chains can be obtained by connecting the following numbered CDRs and FRs in the following combinations: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4.
[0033] The term "vector" refers to a nucleic acid delivery vehicle into which a nucleotide can be inserted. When a vector can express a protein encoded by the inserted polynucleotide, the vector is called an expression vector. The vector can be introduced into a host cell by transformation, transduction or transfection, so that the genetic material elements it carries are expressed in the host cell.
[0034] The vector is well known to those skilled in the art, including but not limited to: plasmid; phagemid; cosmid; artificial chromosome, such as yeast artificial chromosome (YAC), bacterial artificial chromosome (BAC) or P1-derived artificial chromosome (PAC); bacteriophage such as lambda phage or M13 phage and animal virus, etc. Animal viruses that can be used as vectors include but are not limited to retrovirus (including lentivirus), adenovirus, adeno-associated virus, herpes virus (such as herpes simplex virus), poxvirus, baculovirus, papillomavirus, papillomavirus. In some embodiments, the vector of the present invention contains regulatory elements commonly used in genetic engineering, such as enhancers, promoters, internal ribosome entry sites (IRES) and other expression control elements (such as transcription termination signals, or polyadenylation signals and poly-U sequences, etc.).
[0035] In the first aspect, the present invention provides an anti-scopolamine monoclonal antibody, the variable region of the anti-scopolamine monoclonal antibody comprising: a complementary determining region CDR1-VH having an amino acid sequence as shown in SEQ ID NO.1, a complementary determining region CDR2-VH having an amino acid sequence as shown in SEQ ID NO.2, a complementary determining region CDR3-VH having an amino acid sequence as shown in SEQ ID NO.3, a complementary determining region CDR1-VL having an amino acid sequence as shown in SEQ ID NO.4, a complementary determining region CDR2-VL having an amino acid sequence as shown in SEQ ID NO.14, and a complementary determining region CDR3-VL having an amino acid sequence as shown in SEQ ID NO.5.
[0036] The amino acid sequences of SEQ ID NO.1-SEQ ID NO.5 and SEQ ID NO.14 are shown in Table 1.
[0037] Table 1
[0038]
[0039]
[0040] In some optional embodiments, the variable region includes a heavy chain variable region VH having an amino acid sequence as shown in SEQ ID NO.6.
[0041] VKLQQSGGGLVQPGGSLKVSCATSGFTFSDYYMYWVRQTPEKRLE WVAYISNGGGSTYYPDTVKGRFTISSRDNAKNTLYLQMSRLKSEDTAMY YCARHTLYAMDYWGQGTSVTCLL (SEQ ID NO. 6).
[0042] The variable region includes a light chain variable region VL having an amino acid sequence as shown in SEQ ID NO.7.
[0043] DIQMTQTPASLSASVGETVTITCRTSGNIHNYLAWYQQKRGRSPQLL VYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVTLT FGAGTKLELK (SEQ ID NO. 7).
[0044] In some optional embodiments, the anti-scopolamine monoclonal antibody is an IgG antibody.
[0045] In a second aspect, the present invention provides a biomaterial, wherein the biomaterial is selected from any one of ac:
[0046] a. a nucleotide comprising a nucleotide sequence encoding the anti-scopolamine monoclonal antibody;
[0047] b. a vector carrying the nucleotides in a;
[0048] c. A cell, wherein the cell carries the nucleotide described in a, or contains the vector described in b, or expresses the anti-scopolamine monoclonal antibody.
[0049] In a third aspect, the present invention provides a method for preparing the above-mentioned anti-scopolamine monoclonal antibody, which is obtained by fermenting the above-mentioned cells.
[0050] The preparation method is simple and efficient, and a large amount of anti-scopolamine monoclonal antibodies can be obtained through fermentation.
[0051] In a fourth aspect, the present invention provides use of the above-mentioned anti-scopolamine monoclonal antibody in the preparation of a scopolamine detection product.
[0052] The anti-scopolamine monoclonal antibody provided by the present invention can specifically recognize anti-scopolamine, and thus can be used for the detection of scopolamine.
[0053] In a fifth aspect, the present invention provides a scopolamine marker, comprising the anti-scopolamine monoclonal antibody and a marker;
[0054] The anti-scopolamine monoclonal antibody is coupled to a label.
[0055] The marker can be used for specific labeling of anti-scopolamine.
[0056] In some optional embodiments, the marker includes but is not limited to enzymes, fluorescent molecule labels, fluorescent microspheres, colored microspheres, colloidal gold, biotin or streptavidin.
[0057] In a sixth aspect, the present invention provides a kit for detecting scopolamine, the kit comprising the anti-scopolamine monoclonal antibody or the scopolamine marker.
[0058] In some optional embodiments, the kit includes but is not limited to an immunochromatographic detection kit, an ELISA detection kit, an immunomagnetic particle detection kit, an immunofluorescence detection kit or an immunoblot detection kit.
[0059] The present invention is further described below by means of specific examples. However, it should be understood that these examples are only used for more detailed description and should not be construed as limiting the present invention in any form.
[0060] Example 1. Discovery of monoclonal antibody anti-hyoscine-mab1
[0061] 1. Preparation of Scopolamine-BSA Antigen
[0062] Antigen information is shown in the table below.
[0063] Table 2
[0064] Antigen source Antigen name batch number concentration Total use Self-produced antigens Scopolamine #D22091303 5.13mg / ml 5.0mg For immunization and screening
[0065] Scopoletin and BSA were reacted to synthesize scopoletin hapten hyoscine-BSA, and the hapten was used to perform phased immunization on experimental mice.
[0066] 2. Preparation of monoclonal antibody anti-hyoscine-mab1.
[0067] Generally, 6-8 week old healthy Balb / c female mice are selected and immunized according to a pre-specified immunization scheme. The prepared hapten is used as an immunogen to immunize BALB / c mice, and spleen lymphocytes of the successfully immunized mice are extracted. The lymphocytes are fused with mouse myeloma cells SP2 / 0 by cell fusion technology, and after two rounds of subclone screening, a hybridoma cell line that stably secretes anti-scopolamine monoclonal antibodies is obtained, thereby obtaining anti-scopolamine monoclonal antibodies.
[0068] The chemically synthesized hyoscine hapten hyoscine-BSA was used to perform phased immunization on experimental mice.
[0069] The specific steps of animal immunization experiments include:
[0070] 1. Balb / c mice with the same mean body weight and age were randomly divided into two groups: the group with aluminum adjuvant (aluminum hydroxide adjuvant) and the group without aluminum adjuvant.
[0071] 2. Before the experiment, the pre-immune serum of each mouse was collected (pre-immune serum was collected on the fifth day, blood was collected through the eyeball, and an appropriate amount of blood was collected to ensure the normal state of the mice), and the collected serum was stored at 80°C.
[0072] 3. Preparation of the aluminum adjuvant (aluminum hydroxide adjuvant) group: Before immunization, each antigen was diluted to the corresponding dose (75 μg / mouse) in 75 μL PBS, and mixed with alum adjuvant (1 mg / mouse), according to the volume of antigen: adjuvant = 3:1 (i.e., 25 μl adjuvant was added to 75 μl immunogen diluent); the adjuvant was shaken before use, and the injection adjuvant (25 μl) was slowly added to the immunogen solution; after the adjuvant and the immunogen diluent were fully mixed, the two were fully mixed for 30 minutes. The adjuvant effectively adsorbed the antigen; the subsequent operation was carried out according to the immunization animal experiment.
[0073] 4. Group without aluminum adjuvant: The antigens were diluted in 100 μL PBS to the corresponding doses in the above table (75 μg / mouse), and 100 μL of immunogen was added. The subsequent operation was carried out according to the animal immunization experiment.
[0074] 5. Subcutaneous injection at intervals of 2 weeks: The experimental design is a 3-time immunization method, but blood is collected from the eyeball 7 days after each immunization, and part of the mouse supernatant is obtained by centrifugation. The serum titer is first tested. 7 days after the last immunization, blood is collected from the heart to obtain the maximum blood volume, centrifuged to obtain the supernatant, and stored at 80°C;
[0075] 6. Detect serum titer.
[0076] (1) Three mice were immunized, and the mice were numbered A0, A1, and A2. After the three immunizations, scopolamine standard was used for antigen competition detection, and scopolamine hapten hyoscine-BSA was used as coating antigen for indirect ELISA and competitive ELISA to detect the serum titer of immunized mice. The results of the indirect ELISA method were read by an enzyme reader; the results of the competitive ELISA method are shown in Table 3.
[0077] Indirect ELISA method: add 50μl of 1μg / ml coated antigen diluted with coating solution to each well of the enzyme labeling plate, coat overnight at 4℃, wash the plate 3 times with washing solution (PBST) (the same below), add 200μl of blocking solution (5% skim milk powder) to each well, place in a 37℃ incubator for 2h, take out and wash, add 50μl of diluted serum to each well, react in a 37℃ incubator for 30min, wash, add 50μl of goat anti-mouse IgG-HRP solution, react in a 37℃ incubator for 30min. After washing, add 100μl of substrate solution, color in a 37℃ incubator for 10min away from light, and finally add 2mol / LH 2 SO 4, 50 μL was added to terminate the reaction, and the A450 value was read on a microplate reader. The titers of orbital blood of the three mice after three immunizations were all >62500.
[0078] Indirect competitive ELISA: The process of indirect competitive ELISA is mostly the same as that of indirect ELISA, except that the plate is blocked with blocking solution, and after washing the ELISA plate, 50μl of diluted 100ng / ml small molecule scopolamine standard solution is added, followed by 50μl of diluted serum antibody, and the rest of the steps are the same. For the 100ng / ml small molecule scopolamine competition test, the competition rate of 3 mice can reach more than 50% at 1:12500, and fusion can be arranged.
[0079] Unless otherwise specified, the indirect ELISA method and indirect competitive ELISA method used in the following experiments were performed in accordance with the indirect ELISA method and indirect competitive ELISA method of this experiment.
[0080] Table 3 Serum titer test data
[0081]
[0082]
[0083] Note: The hyoscine-BSA serum titer test column in the table is the test result using indirect ELISA test, and the scopolamine standard 100ng / ml column is the competitive ELISA test result using 100ng / ml scopolamine standard for competition (unless otherwise specified, the meanings of the hyoscine-BSA serum titer test column and the scopolamine standard 100ng / ml column in the following table are the same as in this table).
[0084] The immune spleen cells were fused with myeloma cell line SP2 / 0 cells, and the fused cells were screened by HAT selection medium (HAT selection medium contains hypoxanthine, aminopterin and thymidine), and the fused cells were subjected to ELISA positive screening and subcloning; the screened positive monoclonal antibody was purified from ascites using Protein A / G antibody purification column, and the ELISA titer of the purified antibody was >1:128,000, and the purity was >90%.
[0085] 3. Enzyme-linked immunosorbent assay (ELISA) was used to detect the binding activity of scopolamine.
[0086] 1. IgG antibody titer detection method
[0087] (1) Bottom plate coating: Dilute the antigen to be used to 3 μg / ml with coating diluent, add 100 μl of the prepared coating solution to each well, and place in a 4°C refrigerator for 24 h.
[0088] (2) After 24 hours, take the wells out of the refrigerator and place them at 37°C for 30 minutes. Then discard the liquid in the wells and wash the wells three times with washing solution, each time for 3 minutes.
[0089] (3) Blocking the enzyme-labeled reaction wells: Add 200 μl of 5% calf serum to each well and block at 37°C for 90 min. After blocking, wash the wells three times with washing solution, each time for 3 min.
[0090] (4) Add the sample to be tested: dilute the sample according to the required ratio, add the diluted sample to the enzyme-labeled reaction well, 100 μl per well, incubate at 37°C for 90 min; wash the well three times with washing solution, each time for 3 min.
[0091] (5) Add enzyme-labeled antibody: Add secondary antibody of appropriate concentration according to the instructions; incubate at 37°C for 90 min, add 100 μl per well and wash as before.
[0092] (6) Add substrate solution: 100 μl of substrate per well and place at 37°C in the dark for 15 to 30 min.
[0093] (7) Termination reaction: Add 50 μl of stop solution to each well to terminate the reaction and measure the experimental results within 20 min.
[0094] 4. Detect the binding activity of monoclonal antibodies to scopolamine.
[0095] (1) Cell fusion and clone screening data
[0096] The mice were numbered A0, A1, and A2, and four rounds of fusion were completed.
[0097] A total of 1 positive well was selected from the A0 mouse fusion screening, and subcloning was performed to complete a cell line. After fusion screening, a positive clone with an OD450 value of >2.2 was selected for titer detection by multiple dilution, and then a second subclone screening was performed. A cell line was obtained and named A0-1.
[0098] The fusion effect of A1 and A2 mice was poor, with no fusion positive values.
[0099] After three rounds of fusion, a complete cell line was obtained.
[0100] (2) Ascites preparation and testing data
[0101] The A0-1 cell line was injected into three F1 mice to prepare ascites. The titer data after the ascites of the three mice were mixed were as follows:
[0102] Table 4
[0103]
[0104] (3) Exploration of antibody purification conditions and detection data
[0105] The above ascites was purified by 3.3% n-octanoic acid-thiamine precipitation method to obtain antibody A0-1. The antibody titer test data is shown in the following table:
[0106] Table 5
[0107]
[0108] The above data show that the monoclonal antibody of the A0-1 cell line has good specific binding ability to the scopolamine antigen. The scopolamine colloidal gold product detects urine samples, so the standard scopolamine is used for competition experiments. The results show that the A0-1 antibody has a competitive effect on the small molecule scopolamine. Therefore, the A0-1 antibody is selected for the test of the scopolamine colloidal gold product.
[0109] 5. Application of monoclonal antibody anti-hyoscine-mab1 in products.
[0110] Scopolamine antibody A0-1 was verified by immunocolloidal gold platform.
[0111] The A0-1 antibody of scopolamine is labeled with colloidal gold by an immunocolloidal gold platform, and then a colloidal gold chromatography test paper is prepared, wherein the immunochromatographic test paper includes a sample pad, a binding pad and a detection pad, and the detection pad is provided with a detection line and a quality control line. The binding pad is coated with a monoclonal antibody selected and labeled with colloidal gold, the detection line is coated with an antigen of scopolamine, and the quality control line is coated with a sheep anti-mouse IgG antibody. Negative buffer samples and small molecule standards of scopolamine of different concentrations are tested in parallel. When testing negative samples, the small molecule without scopolamine competes with the antigen of scopolamine for binding to the monoclonal antibody labeled with gold, so the antigen of scopolamine coated at the detection line binds to the monoclonal antibody labeled with gold, and the T line is colored.
[0112] Specifically, the experimental group used the scopolamine antibody A0-1 obtained in the above experiment to detect the scopolamine standard of Hangzhou Anxu Biotechnology Co., Ltd. The negative control was a urine sample. The above reagents were added, and then the results were tested using the POCT detection instrument ACG1000 (ID-A003) of Hangzhou Anxu Biotechnology Co., Ltd. The experimental data results are shown in Table 6.
[0113] Table 6
[0114]
[0115] Note: G4-G8 indicates the color depth of the test strip. The higher the value, the darker the color. + / - indicates that the color is slightly darker or lighter than this level. The lower value after adding scopolamine standard indicates that the small molecule has a competitive effect and the antibody can bind to the scopolamine standard.
[0116] The results showed that the gradient of antibody A0-1 was good and it could be used in scopolamine products. The cut-off value reached 100ng / ml. Then the stability of antibody A0-1 was evaluated and three batches of antibody samples were prepared. The evaluation results are as follows:
[0117] Table 7
[0118]
[0119] Based on the product evaluation results, antibody A0-1 was named anti-hyoscine-mab1, which can be used for the detection of scopolamine antigen detection kit.
[0120] 6. Sequence analysis of the heavy chain V region (VH) and light chain V region (VL) of the monoclonal antibody anti-hyoscine-mab1.
[0121] Primers were designed to amplify the heavy chain V region (VH) and light chain V region (VL) genes.
[0122] The primers are as follows:
[0123] Heavy chain variable region forward primer (VH-FOR):
[0124] GGGAATTCGAGGTGCAGCTGCAGGAGTCTGG (SEQ ID NO. 10);
[0125] Heavy chain variable region reverse primer (VH-BACK):
[0126] GGAAGGTGTGCACACCGCTGGAC (SEQ ID NO. 11);
[0127] Light chain variable region forward primer (VL-FOR):
[0128] CACGCTAGGGGCGGCCACTGTGGATCCGGATACAGTTGGTGCAG CATC (SEQ ID NO. 12);
[0129] Light chain variable region reverse primer (VL-BACK):
[0130] GGCTGAGCGGGGCTAGATGCCTCGAGGATATTGTGATAACCCAG (SEQ ID NO. 13).
[0131] Take the hybridoma cell line of anti-hyoscine-mab1 in the logarithmic growth phase (about 10 7 The total RNA of the cells was extracted according to the instruction of Trizol RNA extraction kit, the first chain of cDNA was synthesized by reverse transcription using the total RNA as a template, and the VH / VL gene of the antibody was amplified by PCR using the above amplified product as a template.
[0132] The heavy chain VH (about 360 bp) and light chain VL (about 300 bp) fragments of anti-hyoscine-mab1 were recovered and sent to the company for sequencing.
[0133] Then analyze the VH / VL gene sequences:
[0134] The resulting sequence is as follows:
[0135] Heavy chain variable region sequence:
[0136] anti-hyoscine-mab1 VH:348bp.
[0137] GTGAAACTGCAGCAGTCAGGGGGAGGCTTAGTGCAGCCTGGAGGGTCCCTGAAAGTCTCCTGTGCAACCTCTGGATTCACTTTCAGTGACTATTACATGTATTGGGTTCGCCAGACTCCAGAGAAGAGGCTGGAGTGGGTCGCATACATTAGTAATGGTGGTGGTAGCACCTATTA TCCAGACACTGTAAAGGGCCGATTCACCATCTCCAGAGACAATGCCAAGAACACCCTGTACCTGCAAATGAGCCGTCTGAAGTCTGAGGACACAGCCATGTATTACTGTGCAAGACATACCCTCTATGCTATGGACTACTGGGGTCAAGGAACCTCAGTCACCTGTCTCCTC(SEQ ID NO.8).
[0138] anti-hyoscine-mab1 protein: 116aa.
[0139] VKLQQSGGGLVQPGGSLKVSCATSGFTFSDYYMYWVRQTPEKRLE WVAYISNGGGSTYYPDTVKGRFTISSRDNAKNTLYLQMSRLKSEDTAMY YCARHTLYAMDYWGQGTSVTCLL (SEQ ID NO. 6).
[0140] The variable region sequence of the light chain:
[0141] anti-hyoscine-mab1 LVκ: 321bp.
[0142] GATATCCAGATGACACAGACTCCAGCCTCCCTATCTGCATCTGTGGGAGAAACTGTCACCATCACATGTCGAACAAGTGGGAATATTCACAATTATTTAGCATGGTATCAGCAGAAACGGGGAAGATCTCCTCAGCTCCTGGTCTATAAAGTTTCCAACCGA TTTTCTGGGGTCCCAGACAGGTTCAGTGGCAGTGGATCAGGGACAGATTTCACACTCAAGATCAGCAGAGTGGAGGCTGAGGATCTGGGAGTTTATTTCTGCTCTCAAAGTACACATGTTACGCTCACGTTCGGTGCTGGGACCAAGCTGGAGCTGAAA(SEQ ID NO.9).
[0143] anti-hyoscine-mab1 LVκprotein:107aa.
[0144] DIQMTQTPASLSASVGETVTITCRTSGNIHNYLAWYQQKRGRSPQLL VYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVTLT FGAGTKLELK (SEQ ID NO. 7).
[0145] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein by equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.
Claims
1. A monoclonal antibody against scopolamine, It is characterized in that The variable region of the anti-scopolamine monoclonal antibody includes: a complementary determining region CDR1-VH having an amino acid sequence as shown in SEQ ID NO.1, a complementary determining region CDR2-VH having an amino acid sequence as shown in SEQ ID NO.2, a complementary determining region CDR3-VH having an amino acid sequence as shown in SEQ ID NO.3, a complementary determining region CDR1-VL having an amino acid sequence as shown in SEQ ID NO.4, a complementary determining region CDR2-VL having an amino acid sequence as shown in SEQ ID NO.14, and a complementary determining region CDR3-VL having an amino acid sequence as shown in SEQ ID NO.
5.
2. The anti-scopolamine monoclonal antibody according to claim 1, It is characterized in that The variable region includes a heavy chain variable region VH having an amino acid sequence as shown in SEQ ID NO.6; The variable region includes a light chain variable region VL having an amino acid sequence as shown in SEQ ID NO.
7.
3. The anti-scopolamine monoclonal antibody according to claim 1, It is characterized in that The anti-scopolamine monoclonal antibody is an IgG antibody.
4. Biomaterials, It is characterized in that The biological material is selected from any one of ac: a. a nucleotide comprising a nucleotide sequence encoding the anti-scopolamine monoclonal antibody according to any one of claims 1 to 3; b. a vector carrying the nucleotides in a; c. A cell, wherein the cell carries the nucleotide described in a, or contains the vector described in b, or expresses the anti-scopolamine monoclonal antibody described in any one of claims 1 to 3.
5. A method for preparing the anti-scopolamine monoclonal antibody according to any one of claims 1 to 3, It is characterized in that Obtained by fermentation of the cell described in claim 4.
6. Use of the anti-scopolamine monoclonal antibody according to any one of claims 1 to 3 in the preparation of a scopolamine detection product.
7. A marker for scopolamine, It is characterized in that Comprising the anti-scopolamine monoclonal antibody and a marker according to any one of claims 1 to 3; The anti-scopolamine monoclonal antibody is coupled to a label.
8. The scopolamine marker according to claim 7, It is characterized in that The markers include enzymes, fluorescent molecular markers, fluorescent microspheres, colored microspheres, colloidal gold, biotin or streptavidin.
9. A kit for detecting scopolamine, It is characterized in that The kit comprises the anti-scopolamine monoclonal antibody according to any one of claims 1 to 3 or the scopolamine marker according to claim 7 or 8.
10. The kit according to claim 9, It is characterized in that The kit includes an immunochromatographic detection kit, an ELISA detection kit, an immunomagnetic microparticle detection kit, an immunofluorescence detection kit or an immunoblotting detection kit.
Citation Information
Patent Citations
Hybridoma cell strain capable of secreting scopolamine monoclonal antibody and application of hybridoma cell strain
CN113005098A
Artificial hapten and artificial antigen of scopolamine as well as preparation method and application of artificial hapten and artificial antigen
CN114790203A
